Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC
No Thumbnail Available
Identifiers
Date
2018-10-01
Authors
Mok, T.
Nakagawa, K.
Rosell, R.
Lee, K.
Corral, J.
Migliorino, M. R.
Pluzanski, A.
Linke, R.
Devgan, G.
Sbar, E.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier science inc
Metrics
Export
Abstract
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
dose reduction, non-small cell lung cancer, Dacomitinib